EUVIMEDEUVIMED entdecken
Crossref

The Enhancement of Bone Protective Effect of Sesamin against Rosiglitazone-Induced Bone Loss in Type 2 Diabetic Rats

Krishnaraju Venkatesan, Noohu Abdulla Khan, Sirajudeen Shaik Alavudeen, Vigneshwaran Easwaran, Premalatha Paulsamy, Ester Mary Pappiya, R. Natarajan, Kalpana Krishnaraju, Kumar Venkatesan, Rajalakshimi Vasudevan, Kumarappan Chidambaram

IAR Journal of Pharmacy · 31.08.2021 · 2 (2) · 1-4

DOI: 10.47310/iarjp.2021.v02i02.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IAR Journal of Pharmacy, online erschienen am 31.08.2021. Verfasst von Krishnaraju Venkatesan und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus, especially type 2 diabetes mellitus, is growing more prevalent across the world. Diabetics have a higher risk of mortality and morbidity, as well as cardiomyopathy and nephropathy, since they have a higher chance of bone fractures due to poor Bone Mineral Density (BMD). Diabetic individuals have worse bone quality than non-diabetic patients due to hyper glycemia, the toxic effects of Advanced Glycosylation End Products (AGEs) on bone tissue and an altered bone micro vascular system. Hyperglycemia has been linked to the development of osteoarthritis and osteoporosis. As a result, glucose control is important for bone health in diabetics. Furthermore, research suggests that women who took Rosiglitazone (RSG) had more fractures than those who took other type 2 diabetes medications. Sesamin, a lignan extracted from Fagara plants, has been shown to have anti-osteoporosis therapeutic and preventative properties. Using a diabetic rat model, the goal of this investigation was to see how RSG therapy affects bone quality and whether it might be avoided by co-administration with sesamin. Five groups of six Wistar albino rats were studied: control (vehicle therapy), Streptozotocin (diabetes) group, Sesamin group, Rosiglitazone and Rosiglitazone+Sesamin group. Each medication was given by gastric gavage once a day for 35 days. The Bone Mineral Density (BMD) and Haemoglobin A1c (HbA1c) levels were tested at the end of the therapy period. Consumption of 80 mg/kg Sesamin decreased blood glucose and enhanced BMD in diabetic rats, according to the findings. The researchers discovered that taking 80 mg/kg of Sesamin reduced bone loss caused by RSG by reducing blood glucose and improving BMD. Sesamin combined with RSG appears to be effective in preventing diabetic osteoporosis.

Zitieren

APA

Venkatesan, K., Khan, N. A., Alavudeen, S. S., Easwaran, V., Paulsamy, P., Pappiya, E. M., Natarajan, R., Krishnaraju, K., Venkatesan, K., Vasudevan, R., & Chidambaram, K. (2021). The Enhancement of Bone Protective Effect of Sesamin against Rosiglitazone-Induced Bone Loss in Type 2 Diabetic Rats. IAR Journal of Pharmacy, 2(2), 1-4. https://doi.org/10.47310/iarjp.2021.v02i02.004

Vancouver

Venkatesan K, Khan NA, Alavudeen SS, Easwaran V, Paulsamy P, Pappiya EM, et al. The Enhancement of Bone Protective Effect of Sesamin against Rosiglitazone-Induced Bone Loss in Type 2 Diabetic Rats. IAR Journal of Pharmacy. 2021;2(2):1-4. doi:10.47310/iarjp.2021.v02i02.004

BibTeX
@article{Venkatesan2021,
  author = {Venkatesan, Krishnaraju and Khan, Noohu Abdulla and Alavudeen, Sirajudeen Shaik and Easwaran, Vigneshwaran and Paulsamy, Premalatha and Pappiya, Ester Mary and Natarajan, R. and Krishnaraju, Kalpana and Venkatesan, Kumar and Vasudevan, Rajalakshimi and Chidambaram, Kumarappan},
  title = {The Enhancement of Bone Protective Effect of Sesamin against Rosiglitazone-Induced Bone Loss in Type 2 Diabetic Rats},
  journal = {IAR Journal of Pharmacy},
  year = {2021},
  volume = {2},
  number = {2},
  pages = {1--4},
  doi = {10.47310/iarjp.2021.v02i02.004}
}
Kostenlos starten →